Trials / Completed
CompletedNCT05460455
A Study to Evaluate Multi-dose of HB0034 in Healthy Adult Participants
A Phase Ic, Randomized, Double-blind, Placebo-controlled, Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HB0034 in Adult Healthy Subjects.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The aim of this study is to investigate the safety and tolerability of HB0034 in healthy subjects following multiple-dose.
Detailed description
This is a multi-dose escalation study of HB0034 to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of HB0034.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Recombinant Humanized Anti-IL-36R Monoclonal antibody and Placebo | HB0034 and Placebo |
Timeline
- Start date
- 2022-10-13
- Primary completion
- 2023-06-09
- Completion
- 2023-12-08
- First posted
- 2022-07-15
- Last updated
- 2024-01-23
Locations
1 site across 1 country: New Zealand
Source: ClinicalTrials.gov record NCT05460455. Inclusion in this directory is not an endorsement.